Bayer Yakuhin

Bayer Yakuhin is the Japanese pharmaceutical subsidiary of Bayer AG, a global leader in life sciences. Headquartered in Osaka, the company specializes in the development, manufacturing, and commercialization of innovative prescription drugs across key therapeutic areas including cardiology, oncology, ophthalmology, and women's healthcare. Its robust product portfolio features significant therapies such as the anticoagulant Xarelto, the ophthalmic treatment Eylea, and the prostate cancer drug Nubeqa. Bayer Yakuhin operates as a vital component of Bayer's global research and development network, conducting extensive clinical trials tailored to the Japanese regulatory environment. The company is committed to addressing high unmet medical needs through internal innovation and strategic collaborations with Japanese academic and industrial partners.